Evaluation of ER-α, ER-β1 and ER-β2 expression and correlation with clinicopathologic factors in invasive luminal subtype breast cancers

Clinical and Translational Oncology

Volumn 14, Issue 3, 2012, Pages 225-231

  Zhang, Huiming ^a   Zhang, Zhongtao ^a   Xuan, Lixue ^b   Zheng, Shan ^b   Guo, Lei ^b   Zhan, Qimin ^b   Qu, Xiang ^a   Zhang, Baoning ^b   Wang, Yu ^a   Wang, Xiang ^b   Song, Yongmei ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CANCER HOSPITAL   (China)

Author keywords

Breast cancer; ER 1; ER 2 (ER cx); Immunohistochemistry; Luminal subtype; Prognosis

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA1; ESTROGEN RECEPTOR BETA2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE LUMINAL SUBTYPE BREAST CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGNOSIS; SURVIVAL TIME; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; COHORT STUDIES; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROTEIN ISOFORMS; RECEPTORS, PROGESTERONE; STATISTICS AS TOPIC; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84860703134     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0788-0     Document Type: Article

References (36)

1. Kuiper GG, Enmark E, Pelto-Huikko M et al (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925-5930 (Pubitemid 26190778)
2. Moore JT, McKee DD, Slentz-Kesler K et al (1998) Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 247:75-78 (Pubitemid 28412528)
3. Weihua Z, Andersson S, Cheng G et al (2003) Update on estrogen signaling. FEBS Lett 546:17-24 (Pubitemid 36789762)
4. Ogawa S, Inoue S, Watanabe T et al (1998) Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 26:3505-3512 (Pubitemid 28347221)
5. Järvinen TA, Pelto-Huikko M, Holli K et al (2000) Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 156:29-35 (Pubitemid 30644435)
6. Nakopoulou L, Lazaris AC, Panayotopoulou EG et al (2004) The favourable prognostic value of estrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol 57:523-528 (Pubitemid 38655949)
7. Maehle BO, Collett K, Tretli S et al (2009) Estrogen receptor beta: an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer? APMIS 117:644-650
8. Novelli F, Milella M, Melucci E et al (2008) A divergent role for estrogen receptor-beta in nodepositive and node-negative breast cancer classi? ed according to molecular subtypes: an observational prospective study. Breast Cancer Res 10:R74
9. Fuqua SA, Schiff R, Parra I et al (2003) Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 63:2434-2439 (Pubitemid 36605180)
10. Balfe P, McCann A, McGoldrick A et al (2004) Estrogen receptor alpha and beta pro? ling in human breast cancer. Eur J Surg Oncol 30:469-474 (Pubitemid 38701865)
11. Vinayagam R, Sibson DR, Holcombe C et al (2007) Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer: a retrospective study. BMC Cancer 7:131
12. O'Neill PA, Davies MP, Shaaban AM et al (2004) Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br J Cancer 91:1694-1702 (Pubitemid 39546143)
13. Omoto Y, Kobayashi S, Inoue S et al (2002) Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer 38:380-386 (Pubitemid 34123315)
14. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumors. Nature 406:747-752
15. Yang XR, Sherman ME, Rimm DL et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16:439-443 (Pubitemid 46548646)
16. Spitale A, Mazzola P, Soldini D et al (2009) Breast cancer classi? cation according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. 20:628-635
17. Fox EM, Davis RJ, Shupnik MA (2008) ERbeta in breast cancer: onlooker, passive player, or active protector? Steroids 73:1039-1051
18. Borgquist S, Holm C, Stendahl M et al (2008) Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer. J Clin Pathol 61:197-203
19. Tong D, Schuster E, Seifert M et al (2002) Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines. Breast Cancer Res Treat 71:249-255 (Pubitemid 34263988)
20. Onitilo AA, Engel JM, Greenlee RT et al (2009) Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7:4-13
21. Gillett CE, Barnes DM, Camplejohn RS (1993) Comparison of three cell cycle associated antigens as markers of proliferative activity and prognosis in breast carcinoma. J Clin Pathol 46:1126-1128 (Pubitemid 24022962)
22. Chae BJ, Bae JS, Lee A et al (2009) p53 as a speci? c prognostic factor in triple-negative breast cancer. Jpn J Clin Oncol 39:217-224
23. Honma N, Horii R, Iwase T et al (2008) Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 26:3727-3734
24. Lee JH, Kim SH, Suh YJ et al (2010) Predictors of axillary lymph node metastases (ALNM) in a Korean population with T1-2 breast carcinoma: triple negative breast cancer has a high incidence of ALNM irrespective of the tumor size. Cancer Res Treat 42:30-36
25. Mann S, Laucirica R, Carlson N et al (2001) Estrogen receptor beta expression in invasive breast cancer. Hum Pathol 32:113-118 (Pubitemid 32150637)
26. Honma N, Takubo K, Akiyama F et al (2007) Expression of oestrogen receptor-beta in apocrine carcinomas of the breast. Histopathology 50:425-433 (Pubitemid 46328191)
27. Shaaban AM, Green AR, Karthik S et al (2008) Nuclear and cytoplasmic expression of ERß1, ERß2, and ERß5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 14:5228-5235
28. Honma N, Saji S, Kurabayashi R et al (2008) Oestrogen receptor-beta1 but not oestrogen receptor-betacx is of prognostic value in apocrine carcinoma of the breast. APMIS 116:923-930
29. Sugiura H, Toyama T, Hara Y et al (2007) Expression of estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer. Jpn J Clin Oncol 37:820-828 (Pubitemid 350259000)
30. Poola I, Fuqua SA, De Witty RL et al (2005) Estrogen receptor alpha-negative breast cancer tissues express significant levels of estrogenindependent transcription factors, ERbeta1 and ERbeta5: potential molecular targets for chemoprevention. Clin Cancer Res 11:7579-7585 (Pubitemid 41507721)
31. Pettersson K, Grandien K, Kuiper GG et al (1997) Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha. Mol Endocrinol 11:1486-1496 (Pubitemid 27366759)
32. Kuiper GG, Carlsson B, Grandien K et al (1997) Comparison of the ligand binding speci? city and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138:863-870 (Pubitemid 27089735)
33. Leung YK, Mak P, Hassan S et al (2006) Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci U S A 103:13162-13167 (Pubitemid 44338933)
34. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y et al (2003) Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 22:5011-5020 (Pubitemid 37028337)
35. Davies MP, O'Neill PA, Innes H et al (2004) Correlation of mRNA for oestrogen receptor beta splice variants ERbeta1, ERbeta2/ERbetacx and ERbeta5 with outcome in endocrine-treated breast cancer. J Mol Endocrinol 33:773-782 (Pubitemid 40057569)
36. Esslimani-Sahla M, Kramar A, Simony-Lafontaine J et al (2005) Increased estrogen receptor betacx expression during mammary carcinogenesis. Clin Cancer Res 11:3170-3174 (Pubitemid 40637201)